163 related articles for article (PubMed ID: 24735798)
1. Impact of subdomain D1 of the short form S1b of the human prolactin receptor on its inhibitory action on the function of the long form of the receptor induced by prolactin.
Kang JH; Hassan SA; Zhao P; Tsai-Morris CH; Dufau ML
Biochim Biophys Acta; 2014 Jul; 1840(7):2272-80. PubMed ID: 24735798
[TBL] [Abstract][Full Text] [Related]
2. Intramolecular disulfide bonds of the prolactin receptor short form are required for its inhibitory action on the function of the long form of the receptor.
Xie YL; Hassan SA; Qazi AM; Tsai-Morris CH; Dufau ML
Mol Cell Biol; 2009 May; 29(10):2546-55. PubMed ID: 19273600
[TBL] [Abstract][Full Text] [Related]
3. Ligand-independent homo- and heterodimerization of human prolactin receptor variants: inhibitory action of the short forms by heterodimerization.
Qazi AM; Tsai-Morris CH; Dufau ML
Mol Endocrinol; 2006 Aug; 20(8):1912-23. PubMed ID: 16556730
[TBL] [Abstract][Full Text] [Related]
4. Prolactin receptor gene transcriptional control, regulatory modalities relevant to breast cancer resistance and invasiveness.
Kavarthapu R; Dufau ML
Front Endocrinol (Lausanne); 2022; 13():949396. PubMed ID: 36187116
[TBL] [Abstract][Full Text] [Related]
5. Human prolactin receptor variants in breast cancer: low ratio of short forms to the long-form human prolactin receptor associated with mammary carcinoma.
Meng J; Tsai-Morris CH; Dufau ML
Cancer Res; 2004 Aug; 64(16):5677-82. PubMed ID: 15313907
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of an affinity-matured prolactin complexed to its dimerized receptor reveals the topology of hormone binding site 2.
Broutin I; Jomain JB; Tallet E; van Agthoven J; Raynal B; Hoos S; Kragelund BB; Kelly PA; Ducruix A; England P; Goffin V
J Biol Chem; 2010 Mar; 285(11):8422-33. PubMed ID: 20053995
[TBL] [Abstract][Full Text] [Related]
7. Unmodified prolactin (PRL) and S179D PRL-initiated bioluminescence resonance energy transfer between homo- and hetero-pairs of long and short human PRL receptors in living human cells.
Tan D; Johnson DA; Wu W; Zeng L; Chen YH; Chen WY; Vonderhaar BK; Walker AM
Mol Endocrinol; 2005 May; 19(5):1291-303. PubMed ID: 15695371
[TBL] [Abstract][Full Text] [Related]
8. Functional characterization of the intermediate isoform of the human prolactin receptor.
Kline JB; Roehrs H; Clevenger CV
J Biol Chem; 1999 Dec; 274(50):35461-8. PubMed ID: 10585417
[TBL] [Abstract][Full Text] [Related]
9. S2 deletion variants of human PRL receptors demonstrate that extracellular domain conformation can alter conformation of the intracellular signaling domain.
Tan D; Huang KT; Ueda E; Walker AM
Biochemistry; 2008 Jan; 47(1):479-89. PubMed ID: 18081308
[TBL] [Abstract][Full Text] [Related]
10. Threonine 391 phosphorylation of the human prolactin receptor mediates a novel interaction with 14-3-3 proteins.
Olayioye MA; Guthridge MA; Stomski FC; Lopez AF; Visvader JE; Lindeman GJ
J Biol Chem; 2003 Aug; 278(35):32929-35. PubMed ID: 12819209
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a novel and functional human prolactin receptor isoform (deltaS1PRLr) containing only one extracellular fibronectin-like domain.
Kline JB; Rycyzyn MA; Clevenger CV
Mol Endocrinol; 2002 Oct; 16(10):2310-22. PubMed ID: 12351696
[TBL] [Abstract][Full Text] [Related]
12. Modulation of growth factor receptor function by isoform heterodimerization.
Chang WP; Clevenger CV
Proc Natl Acad Sci U S A; 1996 Jun; 93(12):5947-52. PubMed ID: 8650199
[TBL] [Abstract][Full Text] [Related]
13. Two wrongs can make a right: dimers of prolactin and growth hormone receptor antagonists behave as agonists.
Langenheim JF; Tan D; Walker AM; Chen WY
Mol Endocrinol; 2006 Mar; 20(3):661-74. PubMed ID: 16269515
[TBL] [Abstract][Full Text] [Related]
14. Structural Investigation of Human Prolactin Receptor Transmembrane Domain Homodimerization in a Membrane Environment through Multiscale Simulations.
Minh Hung H; Dieu Hang T; Nguyen MT
J Phys Chem B; 2019 Jun; 123(23):4858-4866. PubMed ID: 31099581
[TBL] [Abstract][Full Text] [Related]
15. Prolactin signal transduction to milk protein genes: carboxy-terminal part of the prolactin receptor and its tyrosine phosphorylation are not obligatory for JAK2 and STAT5 activation.
Goupille O; Daniel N; Bignon C; Jolivet G; Djiane J
Mol Cell Endocrinol; 1997 Mar; 127(2):155-69. PubMed ID: 9099911
[TBL] [Abstract][Full Text] [Related]
16. Structural characterization of the stem-stem dimerization interface between prolactin receptor chains complexed with the natural hormone.
van Agthoven J; Zhang C; Tallet E; Raynal B; Hoos S; Baron B; England P; Goffin V; Broutin I
J Mol Biol; 2010 Nov; 404(1):112-26. PubMed ID: 20875426
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex.
Xu J; Zhang Y; Berry PA; Jiang J; Lobie PE; Langenheim JF; Chen WY; Frank SJ
Mol Endocrinol; 2011 Apr; 25(4):597-610. PubMed ID: 21310852
[TBL] [Abstract][Full Text] [Related]
18. Crystal structure of a prolactin receptor antagonist bound to the extracellular domain of the prolactin receptor.
Svensson LA; Bondensgaard K; Nørskov-Lauritsen L; Christensen L; Becker P; Andersen MD; Maltesen MJ; Rand KD; Breinholt J
J Biol Chem; 2008 Jul; 283(27):19085-94. PubMed ID: 18467331
[TBL] [Abstract][Full Text] [Related]
19. Subdomain 2, Not the Transmembrane Domain, Determines the Dimerization Partner of Growth Hormone Receptor and Prolactin Receptor.
Liu Y; Jiang J; Lepik B; Zhang Y; Zinn KR; Frank SJ
Endocrinology; 2017 Oct; 158(10):3235-3248. PubMed ID: 28977606
[TBL] [Abstract][Full Text] [Related]
20. Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer.
Sakamoto K; Triplett AA; Schuler LA; Wagner KU
Oncogene; 2010 Sep; 29(39):5359-69. PubMed ID: 20639901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
